Dry Eye Disease
01.19.21
Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03 (Perfluorohexyloctane)Source: Bausch + Lomb
01.07.21
Kala Pharmaceuticals Announces Commercial Availability of Eysuvis for the Treatment of Dry Eye DiseaseSource: Kala Pharmaceuticals
12.18.20
Oyster Point Submits NDA to FDA for OC-01 Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye DiseaseSource: Oyster Point Pharma
12.15.20
Palatin Technologies Announces Positive Results From its Phase 2 Study of PL9643 in Patients With Dry Eye DiseaseSource: Palatin Technologies
12.08.20
Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye DiseaseSource: Aldeyra Therapeutics
11.24.20
Report: Dry Eye Treatment Devices Market Size Worth $400.8 Million By 2027Source: Grand View Research, Inc.
11.24.20
Bausch Health Initiates Second Phase 3 Study for Investigational Treatment for Dry Eye Disease Associated With MGDSource: Bausch Health Companies Inc.
11.03.20
Aurinia Pharmaceuticals’ Dry Eye Drug Candidate Does Not Meet Primary EndpointSource: Aurinia Pharmaceuticals